The role of extracellular vesicles in kidney disease progression

Article information

Korean J Nephrol. 2024;.j.krcp.24.201
Publication date (electronic) : 2024 December 20
doi : https://doi.org/10.23876/j.krcp.24.201
1Graduate School of International Agricultural Technology, Seoul National University, Pyeongchang, Republic of Korea
2Institutes of Green-Bio Science Technology, Seoul National University, Pyeongchang, Republic of Korea
Correspondence: Tae Min Kim Graduate School of International Agricultural Technology and Institutes of Green-Bio Science Technology, Seoul National University, 1447 Pyeongchang-daero, Daehwa-myeon, Pyeongchang 25354, Republic of Korea. E-mail: taemin21@snu.ac.kr
Received 2024 July 29; Revised 2024 September 28; Accepted 2024 October 20.

Abstract

Extracellular vesicles (EVs) are nanosized membranous particles released by nearly all cell types, playing a crucial role in mediating cell-to-cell communication. The molecular profile of EVs often reflects that of their originating cells, rendering them valuable for therapeutic and diagnostic purposes. The kidney comprises various cell types, and urinary EVs are predominantly produced from tubular, glomerular, and urinary bladder cells. Within the nephron, EVs produced from the upper segments, such as glomerular tufts and proximal tubules, can be taken up by their downstream counterparts, thereby altering the physiology of recipient cells. Recent studies have demonstrated that this proximal-distal intra-nephron crosstalk via EVs is crucial for normal kidney physiology. Additionally, EVs from interstitial cells (e.g., fibroblasts and macrophages) have been demonstrated to mediate the exacerbation of kidney damage. This review provides up-to-date findings on the function of renal EVs during the progression of renal diseases. Furthermore, we discussed future directions to use the clinical potential of renal EVs as an early biomarker for renal disorders.

Introduction

Extracellular vesicles (EVs) are lipid-bilayered, nanosized vesicles secreted by nearly all cells [1]. Experimental evidence suggests that EVs play a crucial role in intercellular communication, altering the characteristics of recipient cells [24]. Notably, EVs can reflect the physiology of their originating cells, rendering them novel markers for various diseases [57]. Additionally, studies have been actively conducted on the use of EVs from stem/progenitor cells to treat immunological or degenerative diseases [8,9]. Other research has demonstrated the potential of EVs in mediating the progression of various diseases, including inflammation, apoptosis, fibrosis, and cancer [1012].

Kidneys play an essential role in the body, including blood filtration, maintenance of fluid/electrolyte and acid/base balance, removal of drug/toxin metabolites, vitamin D synthesis, erythrocyte production, and blood pressure control [13]. The kidneys are composed of multiple cell types, each with distinct roles, including tubular epithelial cells (TECs), glomerular endothelial cells (GECs), peritubular cells, podocytes, mesangial cells, and juxtaglomerular cells [14]. Following filtration, the glomerular filtrate moves along the tubules and undergoes reabsorption, secretion, and dilution/concentration before excretion. During this intra-nephron journey, EVs from TECs play important roles in normal functions, including protein shuttling (e.g., aquaporin 2 [AQP2]), coagulation processes, innate immunity, and regulation of metabolic activities [15]. However, in vivo physiological status changes continuously, making it challenging to fully understand the detailed function of EVs in the glomerular filtrate in vivo [16]. Moreover, EVs secreted from injured renal cells, including podocytes, tubular cells, and interstitial cells, affect other structures within the nephron, leading to kidney disease progression [17,18]. In this review, we explore the functions of EVs in maintaining kidney homeostasis and the progression of kidney diseases. Furthermore, we discuss the current understanding of the function of renal tubular EVs in the pathological progression of kidney diseases. Additional up-to-date information on the key players involved in communication within the kidney is provided in a previous review by Guo et al. [19]. Due to the large amount of study results, we did not include the literatures on the therapeutic role of stem cell-derived EVs for renal diseases [20].

Basic characteristics of extracellular vesicles

EVs are nanosized particles actively synthesized and released by nearly all cells across various kingdoms, including eukaryotes and prokaryotes [21]. In contrast to the old notion that they are merely a means for cells to remove wastes or unwanted contents, recent studies have identified EVs as key players in maintaining homeostasis [22,23]. Moreover, EVs have been increasingly demonstrated to mediate various diseases, including metabolic and cardiovascular diseases, cancer, neurological disorders, and renal diseases [12,2427]. EVs can reflect the biology of secreting cells and deliver biological messages (e.g., lipids, RNA, and proteins) from these cells to nearby or distant cells, thereby altering the physiology of recipient cells [2830]. Accordingly, the potential use of EVs for therapeutic purposes, drug delivery, or biomarker development is now under intense investigation [3133]. Conventionally, EVs are classified as exosomes, microvesicles (MVs), and apoptotic bodies. Exosomes (30–120 nm) originate from multivesicular bodies, which fuse with the plasma membrane, releasing exosomes into the extracellular space [34]. MVs (150–1,000 nm) originate from ectosomes, which protrude and cleave from the plasma membrane [34]. Apoptotic vesicles (100–5,000 nm) are large cytoplasmic fragments produced during apoptotic cell death [34,35]. Detailed mechanisms of their biosynthesis and characteristics are provided in previous reviews [36,37].

Current reports on the role of extracellular vesicle-mediated communication between kidney cells: early proof-of-concept studies

In the kidney, the glomerular compartments mediate blood filtration, whereas the tubular compartments are important for the reabsorption/secretion processes, as well as the concentration of filtrates [38]. EVs released by various renal cells play a crucial role in the communication between different parts of the nephron [11]. The sources of urinary EVs are diverse, including several parts of the nephron, such as glomerular podocytes, proximal/distal tubular cells, Henle’s loop, and the collecting duct. An early report that the proteome contents of EVs isolated from normal human urine are from apical plasma membrane channel and transport proteins, with no expression of basolateral membrane integral membrane proteins. These results indicate that most urinary EVs are derived from the apical plasma membrane, suggesting the potential of the urinary EV for diagnostic uses for tubular diseases [39].

In 2011, Street et al. [40] showed that the expression of AQP2 protein in exosomes derived from collecting duct cells treated with desmopressin (vasopressin analog) was increased. Moreover, AQP2 from exosomes could be delivered to nearby cells, marking the first in vitro demonstration of cell-to-cell communication between renal cells [40]. Additionally, an in vitro study demonstrated that EVs released from proximal tubule cells have been demonstrated to be taken up by distal tubule and collecting duct cells, reducing reactive oxygen species production in recipient cells [41]. A subsequent in vitro study demonstrated that glyceraldehyde-3-phosphate dehydrogenase–expressing exosomes derived from cultured proximal tubular cells are transferred to the distal tubule and collecting duct cells, leading to a decrease in sodium ion reabsorption [42]. However, it may be important to determine to what extent the horizontal biomolecule transfer is mediated by EVs. For example, non-EV-mediated RNA shuttling in nephron can also occur; in a podocyte-specific uracil phosphoribosyl transferase-expressing mice, the podocyte-specific RNA was detected in the tubular cells upon being injected with 4-thiouracil, which enables the T>C detection after RNA sequencing. It would be interesting to further examine whether the transcripts from podocyte-derived EVs can be incorporated into the TECs, at least in vitro [43].

Functions of extracellular vesicles in renal pathophysiology

Extracellular vesicles from glomerular endothelial and mesangial cells

Prolonged hyperglycemia can induce macro- or microvascular complications in the glomerulus, ultimately leading to chronic kidney disease (CKD). Consequently, several studies have focused on the effects of EVs derived from glomerular cells on other downstream tubular compartments (Table 1). For example, microRNA (miRNA)-200c-3p, transferred via EVs secreted from lipopolysaccharide (LPS)- or high glucose (HG)-treated GECs, have been demonstrated to reduce vascular endothelial growth factor expression in podocytes, leading to podocyte dysfunction [44]. Similarly, exosomal transforming growth factor-beta 1 (TGF-β1) messenger RNA released from GECs in diabetic mice impaired the function of mouse podocytes and induced epithelial-to-mesenchymal transition (EMT) by augmenting alpha-smooth muscle actin (α-SMA) and ferroptosis suppressor protein 1 expression while reducing zonula occludens-1 (ZO-1) and Wilms’ tumor-1 expression [45]. Furthermore, EVs derived from glomerular mesangial cells (GMCs) subjected to HG conditions stimulated the protein expression of p-AKT, p-p65, and TGF-β1, ultimately reducing apoptosis in podocytes [46]. A recent study demonstrated that intercellular shuttling of circular (circ) RNAs from GECs cultured under HG conditions can provoke the EMT of GMCs; exosomes from HG-treated GECs suppressed GMC proliferation and increased α-SMA expression. Mechanistic studies demonstrated that these changes were mediated by circRNF169-2 and circSTRN3-2 located in the exosomes of HG-treated GECs [47]. These results suggest that various glomerular cells release EVs, which induce changes in the expression of recipient cells within the glomerulus.

Molecular contents and function of EVs derived from glomerular cells and their pathological roles in kidney cells

Effect of extracellular vesicles from podocytes on renal tubular cells

Podocyte injury is a major factor in the onset of diabetic kidney disease (DKD). Therefore, studies have investigated the effects of EVs from podocytes cultured under HG conditions on other renal cells (Table 1). For example, EVs from HG-cultured podocytes have been demonstrated to exhibit higher levels of miR-221 than those cultured under low-glucose conditions. MiR-221 in these EVs downregulated dickkopf-related protein 2 expression in tubular cells, leading to a reduction in ZO-1 and e-cadherin (E-CAD) expression. Additionally, the nuclear translocation of β-catenin increased the expression levels of α-SMA and vimentin (VIM). However, in vivo inhibition of miR-221 using an antagomir reduced proximal tubular injury in streptozotocin (STZ)-induced diabetic mice [48]. Another study demonstrated that HG-treated mouse podocytes induced apoptosis in proximal TECs (PTECs). Functional enrichment analysis revealed that five differentially expressed miRNAs (mmu-miR-1981-3p, mmu-miR-3747, mmu-miR-7224-3p, mmu-miR-6538, and mmu-miR-let-7f-2-3p) from these podocytes were enriched in pathways related to DKD progression [49].

The role of podocyte-derived microparticles in the mesenchymal transition of tubular cells has also been demonstrated. For example, it was shown that microparticles from podocytes, as evidenced by podocalyxin-positive nano-size particles by flow cytometry, were increased in both STZ-treated and Akita mice before the onset of albuminuria [50]. Few years later, the same group revealed that microparticles released from a human podocyte cell line increased p38 and Smad3 phosphorylation in human PTECs. Additionally, these EVs increased the expression of extracellular matrix (ECM) proteins such as fibronectin and collagen type IV (COL4) in PTECs, resulting in a profibrotic response in vitro [51]. Puromycin aminonucleosides (PAN) are widely used to induce experimental nephrotic syndrome both in vitro and in vivo. Jeon et al. [52] demonstrated that EVs from PAN-treated human podocytes induced apoptosis and increased the levels of cleaved poly(ADP-ribose) polymerase, phosphorylated extracellular signal-regulated kinase, p-p38, fibronectin, and COL4 in renal TECs. Notably, two upregulated miRNAs (miR-149, -424) have been demonstrated to induce the apoptosis of HK-2 cells [52]. These results indicate that podocyte-driven EVs can trigger fibrotic changes and apoptosis in TECs.

Extracellular vesicles from renal tubular cells

TECs are the most widely used source of EVs, and several studies have explored the interactions between TEC-derived EVs and other renal cells (Table 2). Recent studies have demonstrated that EVs released by injured TECs induce phenotypic changes in other cells and promote disease progression (Fig. 1). For example, EVs derived from TGF-β1–treated renal TECs (NRK-52E) have been demonstrated to stimulate the expression of fibroblast markers α-SMA and fibronectin in renal fibroblasts (NRK-49F) via miR-21 in vitro. Similarly, the expression of fibrotic markers was observed after these EVs were injected into a mouse model of renal fibrosis (unilateral ureteral obstruction, UUO) [53]. Another study demonstrated that EVs derived from TGF-β1–treated human renal epithelial cells (HK-2) decreased apoptotic death in renal interstitial fibroblasts while stimulating fibrotic changes in the renal parenchyma of UUO mice. Specifically, the study revealed that exosomal tumor necrosis factor-alpha (TNF-α)-induced protein 8 (TNFAIP8) enhanced p53 ubiquitination, which inhibited apoptosis and induced the proliferation of renal interstitial fibroblasts [54].

Molecular contents of EVs derived from tubular epithelial cells and their pathological roles in kidney

Figure 1.

The roles of EVs from TECs during the onset of renal diseases.

EVs from TECs can deliver biomolecules to other cells within the nephron. External signals, such as fibrotic stimulus (TGF-β1), high glucose, protein (BSA), or hypoxia, stimulate TECs, inducing EV production. Subsequently, EVs are taken up by other cells, contributing to inflammation through M1 polarization of macrophages and fibrosis via myofibroblastic activation of renal fibroblasts and mesangial cells.

BSA, bovine serum albumin; CCL2, chemokine (C-C motif) ligand 2; EV, extracellular vesicles; TEC, tubular epithelial cells; TGF-β1, transforming growth factor-beta 1; TNFAIP8, tumor necrosis factor-alpha-induced protein 8.

Hyperglycemia can contribute to fibrotic diseases by affecting not only the glomerulus but also renal TECs [55]. Tsai et al. [56] demonstrated that EVs from HK-2 cells cultured in an HG medium induced the transformation of mesangial cells into myofibroblasts. Subsequent analyses revealed that exosomal miR-92a-1-5p was responsible for this change. Moreover, diabetic nephropathy was induced in mice injected with these EVs [56]. Another study suggested that EVs secreted from mouse proximal TECs cultured under HG conditions not only altered cell morphology but also increased the expression of fibroblast markers such as fibronectin, α-SMA, and COL4 in renal fibroblasts (NRK-49F) [57].

Macrophage polarization is also affected by the release of EVs from injured TECs. For example, EVs from TGF-β–treated TECs have been demonstrated to induce the expression of inducible nitric oxide synthase (iNOS), α-SMA, TNF-α, and interleukin (IL)-10 in Raw 264.7 macrophages, leading to their polarization into the M1 type [58]. Another study revealed that the expression of inflammatory cytokines, including TNF-α and IL-6, was increased in Raw 264.7 macrophages co-cultured with EVs secreted from bovine serum albumin-treated mouse TECs. Notably, chemokine (C-C motif) ligand 2 and miR-19b-3p within these EVs were identified as the key contributors to renal inflammation caused by M1-polarized macrophages [59,60].

Prolonged hypoxia induces various renal injuries, with proximal tubular cells being susceptible to hypoxic injury. For example, miR-374b-5p from the exosomes of hypoxic TECs has been demonstrated to promote M1 polarization in Raw 264.7 cells. In a mouse model of renal ischemia-reperfusion, injury was more severe in mice receiving these EVs compared to those receiving EVs from normoxic TECs. Furthermore, miR-374b-5p blockade in mice subjected to ischemia/reperfusion injury improved kidney injury by reducing the expression of proinflammatory cytokines and inhibiting M1-polarization [61]. Another study revealed that forced expression of HIF-1α in TECs led to the shedding of miRNA-23a–enriched exosomes in vivo, which contributed to tubulointerstitial inflammation after ischemic injury. These exosomes promoted the expression of inflammatory markers, such as TNF-α and IL-β1, in Raw 264.7 macrophages, with miR-23a inhibition disrupting these changes. Furthermore, healthy mice injected with these EVs exhibited increased interstitial damage macrophage infiltration [62]. Another study demonstrated that renal fibrosis induced by unilateral ischemia-reperfusion injury worsened upon injection with miR-150-5p–enriched exosomes secreted from hypoxia-cultured TECs (NRK-52E); however, these changes were reversed by miR-150-5p–deficient exosomes. Mechanistically, miR-150-5p regulates suppressor of cytokine signaling 1, which negatively regulates the JAK/STAT pathway, leading to an increase in proinflammatory factors, cell apoptosis, and renal fibrosis [63,64]. These studies showed that TEC-derived EVs have mainly focused on the effects of EVs derived from TECs undergoing hypoxic injury. In vitro studies have shown activation of fibroblasts, upregulation of fibrosis markers, and polarization of macrophages towards a proinflammatory M1 phenotype. Similarly, in vivo, increased inflammation and fibrosis have been observed when TEC-derived EVs are injected into acute kidney injury (AKI), CKD models. In contrast these studies (where hypoxia was given for more than 24 hours), it was reported that short-term ischemic preconditioning (4 hours) of TEC reduced fibrosis followed by renal ischemia/reperfusion injury [65]. The underlying mechanism of this protective mechanism is unknown, but is likely to be due to altered characteristics of TECs by hypoxic conditioning, which had widely used for potentiating the therapeutic effect reported in mesenchymal stem cells (MSCs) [66]. Collectively, these findings suggest that TEC-derived EVs affect the progression of renal diseases.

Extracellular vesicles from other cells

Although located outside the nephron, EVs from blood cells or kidney-resident non-epithelial cells can contribute to kidney diseases [12] (Table 3). Fibroblasts in the kidneys are critical for maintaining organ architecture through ECM homeostasis, water and electrolyte control, and erythropoietin production [67]. These cells express immune receptors, including Toll-like receptors, indicating that they can respond to various injurious stimuli, such as damage-associated molecular patterns [68,69]. Persistent inflammation or fibrotic signals can activate renal fibroblasts into myofibroblasts, a major cell type responsible for excessive ECM production, leading to maladaptive tubular repair and interstitial fibrosis [70]. Zhou et al. [71] demonstrated that the number of MVs from TGF-β1–treated renal fibroblasts was higher than that from untreated cells, with miR-34a being enriched in these MVs. Notably, treatment with these MVs increased tubular cell death, and this apoptotic effect was mediated by miR-34a in vitro. Furthermore, these MVs migrated to the nephron via a disrupted tubular basement membrane [71,72]. These findings indicate that fibrotic signals can activate the fibroblast-myofibroblast transition, which subsequently triggers tubular cell death, tubulointerstitial fibrosis, and decreased renal function.

Effects of EVs from other cells on their pathological role in kidney cells

Endothelial colony-forming cells and myeloid angiogenic cells are proangiogenic hematopoietic cells derived from peripheral blood-derived mononuclear cells [73]. Before this statement report, Cantaluppi et al. [74] demonstrated that MVs from blood-derived undefined pro-angiogenic cells (named ‘endothelial progenitor cells [EPCs]’ in this literature) alleviated chronic renal injury after ischemia-reperfusion injury in mice, as evidenced by improved renal function, reduced apoptosis, and decreased immune cell infiltration. Further analysis revealed that these effects were mediated by miR-126 and miR-296 within the MVs, indicating that the protective role of EPCs is associated with the delivery of RNA contents [74].

Macrophages play a crucial role in tissue repair and injury. Tang et al. [75] demonstrated that EVs from IL-10–transfected Raw 264.7 cells, which were subsequently differentiated into M2 macrophages, improved renal tubular injury and inflammation after ischemia-reperfusion injury and CKD transition. This improvement was linked to the suppression of mTOR signaling and the enhancement of mitochondrial function through mitophagy activation in TECs. Furthermore, IL-10+ EVs increased CD206 expression while reducing CD68 levels, indicating their role in driving M2 polarization in the injured kidney [75]. Another study demonstrated that exosomal miR-25-3p secreted by M2 macrophages improved HG-induced podocyte injury, evidenced by increased autophagic activity and higher levels of placental cadherin, ZO-1, and E-CAD, alongside reduced levels of VIM and α-SMA. The same study revealed that exosomal miR-25-5p suppressed the expression of dual specificity phosphatase 1, which promoted podocyte autophagy [76]. Another study demonstrated that EVs derived from macrophages under high hyperglycemic conditions stimulated mouse podocyte apoptosis via miR-25-3p and miR-21a-5p [77]. Similarly, exosomes released from M2 macrophages were enriched with miR-93-5p, targeting the Toll-like receptor 4 pathway, thereby suppressing apoptosis in LPS-induced mouse podocytes [78]. In addition, urinary EVs carrying klotho from healthy individuals demonstrated renoprotective effects, as indicated by improved renal function and reduced expression of neutrophil gelatinase-associated lipocalin (NGAL) and plasminogen activator inhibitor in the kidneys of rhabdomyolysis-induced AKI mice receiving these EVs [79].

The potential of renal extracellular vesicles for clinical application

Since the molecular profile of EVs can represent the traits of the parental cells, EVs hold tremendous potential for biomarker development in various conditions such as AKI, CKD, immunoglobulin A nephropathy, graft function and kidney transplantation, and nephrotic syndrome [80]. Conventional methods for diagnosing renal function include serum creatinine level, urine output, and glomerular filtration rate. However, these parameters can be affected by other factors, and they may not be suitable for early detection of AKI, CKD, and graft rejection after kidney transplantation. Importantly, changes in the biomolecular profile in urinary EVs can occur before creatinine level changes, which makes early diagnosis possible [12]. Moreover, EVs can be easily obtained routinely in noninvasive way, and their contents remain stable even under unfavorable conditions (high/low pH, freeze-thaw cycles, cryopreservation, etc.). Thus, their basic characteristics (numbers and size) and biomolecular contents made EV an ideal material for biomarker development.

For example, Lange et al. [81] has shown that miR-21 is highly expressed in EVs isolated from the urine of CKD patients, correlating with podocyte damage. In type 2 diabetes mellitus, miR-192, an early biomarker for diabetic nephropathy, is significantly upregulated in urinary EVs from patients with microalbuminuria [82]. Another study found that miRNA-181a, a promising biomarker for early diagnosis, is expressed at lower levels in urinary exosomes from CKD patients compared to healthy individuals [83]. In kidney transplantation, detecting or predicting graft rejection is of critical importance to reduce graft loss. It was shown that the proteins in urinary exosomes were superior to those from whole urine in predicting acute rejection. Specifically, eleven proteins were functionally involved in stress response and inflammation, among which three were exclusively detected in urinary exosome [84]. Another study demonstrated that the protein expression of NGAL, one of the markers for delayed graft function (DGF) after KT, was higher in the urinary exosomes of DGF patients compared with non-DGF patients [85]. These ongoing studies into urinary EV biomarkers in kidney disease could greatly enhance the clinical utility of urine tests for disease diagnosis and monitoring.

Controlling EV release or uptake has been proposed as a novel therapeutic approach. For example, the kinin system is essential during vasculitis as well as chronic inflammation [86]. One study observed that a higher number of B1 receptor (kinin receptor)-positive MVs are released from in vitro cultured GECs upon stimulation with the plasma from acute vasculitis. Importantly, blocking the kinin system by a C1 inhibitor reduced the release of B1 receptor-carrying MVs, highlighting its potential in mitigating neutrophil-driven inflammation by MVs [87]. In another study, Liu et al. [88] showed that blocking tubular exosome secretion in UUO mice prevented renal fibrosis, providing strong evidence that early intervention approach by blocking exosome secretion during acute injury could be another stragety for fibrotic diseases. While further research is needed to determine whether modulating EV release and uptake directly impacts the progression of kidney disease, these findings suggest that EVs may serve as promising therapeutic targets. Studies on the development of therapeutics and drug delivery tools utilizing engineered or native EVs are also under extensive research [89].

Despite significant research efforts, several obstacles remain in the clinical application of EVs. Most of all, standardized guidelines for collection, storing, and documenting plasma or urinary EVs should be established. Also, the criteria for selecting biomarker sets should be critically determined based on the large amount of data combined with clinical information. For therapeutic uses, quality controlling of EVs (e.g., purity, concentration, stability, and pharmaceutical activity of active biomolecular cargo, etc.), determination of dosage and administration, efficacy as well as safety study should be critically performed and evaluated according to the regulatory policies. Lastly, developing efficient manufacturing protocols is essential for the consistent and reliable production of high-quality EVs.

Future directions

Although it is becoming evident that EVs play an important role in normal kidney function and the progression of renal diseases, their specific roles in the kidney remain largely unexplored. Understanding how various contexts—such as hypoxia, hyperglycemia, hypertension, nephrotoxins, or nutrient deprivation—affect the physicochemical properties of EVs (e.g., types and sizes) in specific cell types is imperative [36]. Next, the molecular components of renal EVs, such as lipids, proteins, and nucleic acids, and their functions in target cells should be determined. With the advancement of high-throughput multiomic tools, efforts aimed at determining the molecular functions, including cell death, proliferation, inflammation, fibrosis, senescence, and autophagy, associated with the biomolecular fingerprints within EVs are expected to increase. Although not fully covered in this review, the identification of early biomarkers in urinary EVs for renal diseases is expanding. As these EVs reflect the status of kidney malfunction, molecular profiling of urinary EVs can serve as a starting point for investigating how EVs function in various complications as well as developing early biomarkers. It should be noted that a large part of the studies discussed in this review are based on in vitro or animal studies, and further studies are warranted to translate into clinical findings.

Additionally, the potential of stem/progenitor cell-derived EVs for therapeutic purposes has well been documented. Since the first report on the protective role of MVs from human bone marrow-derived mesenchymal stem cells in AKI, it is now becoming evident that the therapeutic effect of MSCs is largely derived from their paracrine actions as well as secreted EVs, not by direct replacement of damaged cells [90,91]. Since these two studies, the renoprotective role of EVs from various cultured cells including MSCs, iPSCs, liver stem cells, macrophages, urinary stem cells, TECs, neutrophils, as well as non-cultured sources (red blood cells, urine) has been reported in various diseases (AKI, CKD, diabetic nephropathy) [9,92]. However, the development of scalable and standardized protocols for generating, storing, functional testing, and delivery methods of EVs are needed [93,94].

Conclusions

EVs are released from all nephronal compartments and mediate cell-to-cell communication within the luminal space. The molecular profile of EVs often reflects the characteristics of their originating cells, rendering them valuable for developing diagnostic markers. In addition, EVs from upstream nephron segments of the nephron can be transported to downstream cells, delivering biological molecules and altering the physiology of recipient cells. This intra-nephron communication is crucial for both normal physiology and disease progression in the kidney. Over the next decade, in-depth studies on the function of the biomolecular profiles of EVs from different nephron segments will enhance the understanding of how initial results can be amplified. Ultimately, identifying specific biomolecules within EVs may provide us insight into how renal diseases are propagated, and this information will contribute to development of early biomarkers for various renal diseases.

Notes

Conflicts of interest

All authors have no conflicts of interest to declare.

Funding

This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MIST) (RS-2024-00336067).

Data sharing statement

The data presented in this study are available from the corresponding author upon reasonable request.

Authors’ contributions

Conceptualization, Funding acquisition: TMK

Methodology: RK, TMK

Writing–original draft: RK

Writing–reviewing & editing: RK, TMK

All authors read and approved the final manuscript.

References

1. Abels ER, Breakefield XO. Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake. Cell Mol Neurobiol 2016;36:301–312. 10.1007/s10571-016-0366-z. 27053351.
2. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science 2020;367eaau6977. 32029601.
3. Foster BP, Balassa T, Benen TD, et al. Extracellular vesicles in blood, milk and body fluids of the female and male urogenital tract and with special regard to reproduction. Crit Rev Clin Lab Sci 2016;53:379–395. 10.1080/10408363.2016.1190682. 27191915.
4. Admyre C, Johansson SM, Qazi KR, et al. Exosomes with immune modulatory features are present in human breast milk. J Immunol 2007;179:1969–1978. 10.4049/jimmunol.179.3.1969. 17641064.
5. Pullan JE, Confeld MI, Osborn JK, Kim J, Sarkar K, Mallik S. Exosomes as drug carriers for cancer therapy. Mol Pharm 2019;16:1789–1798. 10.1021/acs.molpharmaceut.9b00104. 30951627.
6. Skotland T, Sagini K, Sandvig K, Llorente A. An emerging focus on lipids in extracellular vesicles. Adv Drug Deliv Rev 2020;159:308–321. 10.1016/j.addr.2020.03.002. 32151658.
7. Willms E, Cabañas C, Mäger I, Wood MJ, Vader P. Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and diverse functions in cancer progression. Front Immunol 2018;9:738. 10.3389/fimmu.2018.00738. 29760691.
8. Wang C, Li SW, Zhong X, Liu BC, Lv LL. An update on renal fibrosis: from mechanisms to therapeutic strategies with a focus on extracellular vesicles. Kidney Res Clin Pract 2023;42:174–187. 10.23876/j.krcp.22.159. 37037480.
9. Nowak N, Yamanouchi M, Satake E. The nephroprotective properties of extracellular vesicles in experimental models of chronic kidney disease: a systematic review. Stem Cell Rev Rep 2022;18:902–932. 10.1007/s12015-021-10189-9. 34110587.
10. Yuana Y, Sturk A, Nieuwland R. Extracellular vesicles in physiological and pathological conditions. Blood Rev 2013;27:31–39. 10.1016/j.blre.2012.12.002. 23261067.
11. Ståhl AL, Johansson K, Mossberg M, Kahn R, Karpman D. Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases. Pediatr Nephrol 2019;34:11–30. 10.1007/s00467-017-3816-z. 29181712.
12. Grange C, Bussolati B. Extracellular vesicles in kidney disease. Nat Rev Nephrol 2022;18:499–513. 10.1038/s41581-022-00586-9. 35641620.
13. Zoccali C, Mallamaci F, Lightstone L, et al. A new era in the science and care of kidney diseases. Nat Rev Nephrol 2024;20:460–472. 10.1038/s41581-024-00828-y. 38575770.
14. Tanaka S, Portilla D, Okusa MD. Role of perivascular cells in kidney homeostasis, inflammation, repair and fibrosis. Nat Rev Nephrol 2023;19:721–732. 10.1038/s41581-023-00752-7. 37608184.
15. Grange C, Dalmasso A, Cortez JJ, Spokeviciute B, Bussolati B. Exploring the role of urinary extracellular vesicles in kidney physiology, aging, and disease progression. Am J Physiol Cell Physiol 2023;325:C1439–C1450. 10.1152/ajpcell.00349.2023. 37842748.
16. Agborbesong E, Bissler J, Li X. Liquid biopsy at the frontier of kidney diseases: application of exosomes in diagnostics and therapeutics. Genes (Basel) 2023;14:1367. 10.3390/genes14071367. 37510273.
17. Ichii O, Otsuka-Kanazawa S, Horino T, et al. Decreased miR-26a expression correlates with the progression of podocyte injury in autoimmune glomerulonephritis. PLoS One 2014;9e110383. 10.1371/journal.pone.0110383. 25329154.
18. Tsai YC, Kuo MC, Hung WW, et al. High glucose induces mesangial cell apoptosis through miR-15b-5p and promotes diabetic nephropathy by extracellular vesicle delivery. Mol Ther 2020;28:963–974. 10.1016/j.ymthe.2020.01.014. 31991106.
19. Guo C, Cui Y, Jiao M, et al. Crosstalk between proximal tubular epithelial cells and other interstitial cells in tubulointerstitial fibrosis after renal injury. Front Endocrinol (Lausanne) 2024;14:1256375. 10.3389/fendo.2023.1256375. 38260142.
20. Roszkowski S. Therapeutic potential of mesenchymal stem cell-derived exosomes for regenerative medicine applications. Clin Exp Med 2024;24:46. 10.1007/s10238-023-01282-z. 38427086.
21. Woith E, Fuhrmann G, Melzig MF. Extracellular vesicles: connecting kingdoms. Int J Mol Sci 2019;20:5695. 10.3390/ijms20225695. 31739393.
22. Takahashi A, Okada R, Nagao K, et al. Exosomes maintain cellular homeostasis by excreting harmful DNA from cells. Nat Commun 2017;8:15287. 10.1038/ncomms15287. 28508895.
23. Stahl PD, Raposo G. Extracellular vesicles: exosomes and microvesicles, integrators of homeostasis. Physiology (Bethesda) 2019;34:169–177. 10.1152/physiol.00045.2018. 30968753.
24. Akbar N, Azzimato V, Choudhury RP, Aouadi M. Extracellular vesicles in metabolic disease. Diabetologia 2019;62:2179–2187. 10.1007/s00125-019-05014-5. 31690986.
25. Jansen F, Nickenig G, Werner N. Extracellular vesicles in cardiovascular disease: potential applications in diagnosis, prognosis, and epidemiology. Circ Res 2017;120:1649–1657. 28495995.
26. Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer: implications for future improvements in cancer care. Nat Rev Clin Oncol 2018;15:617–638. 10.1038/s41571-018-0036-9. 29795272.
27. Mazurskyy A, Howitt J. Extracellular vesicles in neurological disorders. Subcell Biochem 2021;97:411–436. 10.1007/978-3-030-67171-6_16. 33779926.
28. Fyfe J, Casari I, Manfredi M, Falasca M. Role of lipid signalling in extracellular vesicles-mediated cell-to-cell communication. Cytokine Growth Factor Rev 2023;73:20–26. 10.1016/j.cytogfr.2023.08.006. 37648617.
29. Ratajczak J, Miekus K, Kucia M, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006;20:847–856. 10.1038/sj.leu.2404132. 16453000.
30. Jiang N, Xiang L, He L, et al. Exosomes mediate epithelium-mesenchyme crosstalk in organ development. ACS Nano 2017;11:7736–7746. 10.1021/acsnano.7b01087. 28727410.
31. Zhu J, Wang S, Yang D, Xu W, Qian H. Extracellular vesicles: emerging roles, biomarkers and therapeutic strategies in fibrotic diseases. J Nanobiotechnology 2023;21:164. 10.1186/s12951-023-01921-3. 37221595.
32. Herrmann IK, Wood MJ, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol 2021;16:748–759. 10.1038/s41565-021-00931-2. 34211166.
33. Murphy DE, de Jong OG, Brouwer M, et al. Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking. Exp Mol Med 2019;51:1–12. 10.1038/s12276-019-0223-5.
34. Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol 2019;21:9–17. 10.1038/s41556-018-0250-9. 30602770.
35. Atkin-Smith GK, Tixeira R, Paone S, et al. A novel mechanism of generating extracellular vesicles during apoptosis via a beads-on-a-string membrane structure. Nat Commun 2015;6:7439. 10.1038/ncomms8439. 26074490.
36. Jeppesen DK, Zhang Q, Franklin JL, Coffey RJ. Extracellular vesicles and nanoparticles: emerging complexities. Trends Cell Biol 2023;33:667–681. 10.1016/j.tcb.2023.01.002. 36737375.
37. Cecchin R, Troyer Z, Witwer K, Morris KV. Extracellular vesicles: the next generation in gene therapy delivery. Mol Ther 2023;31:1225–1230. 10.1016/j.ymthe.2023.01.021. 36698310.
38. Thompson LE, Joy MS. Endogenous markers of kidney function and renal drug clearance processes of filtration, secretion, and reabsorption. Curr Opin Toxicol 2022;31:100344. 10.1016/j.cotox.2022.03.005. 36777447.
39. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A 2004;101:13368–13373. 10.1073/pnas.0403453101. 15326289.
40. Street JM, Birkhoff W, Menzies RI, Webb DJ, Bailey MA, Dear JW. Exosomal transmission of functional aquaporin 2 in kidney cortical collecting duct cells. J Physiol 2011;589:6119–6127. 10.1113/jphysiol.2011.220277. 22025668.
41. Gildea JJ, Seaton JE, Victor KG, et al. Exosomal transfer from human renal proximal tubule cells to distal tubule and collecting duct cells. Clin Biochem 2014;47:89–94. 10.1016/j.clinbiochem.2014.06.018. 24976626.
42. Jella KK, Yu L, Yue Q, Friedman D, Duke BJ, Alli AA. Exosomal GAPDH from proximal tubule cells regulate ENaC activity. PLoS One 2016;11e0165763. 10.1371/journal.pone.0165763. 27802315.
43. Hunter RW, Kumar S, Coward RJM, Buck AH, Dear JW. Extracellular RNA moves from the glomerulus to the renal tubule. bioRxiv 448584 [Preprint]. bioRxiv; 2021 [cited 2021 Jun 15]. Available from: https://www.biorxiv.org/content/10.1101/2021.06.15.448584v1. DOI: 10.1101/2021.06.15.448584. 10.1101/2021.06.15.448584.
44. Hill N, Michell DL, Ramirez-Solano M, et al. Glomerular endothelial derived vesicles mediate podocyte dysfunction: a potential role for miRNA. PLoS One 2020;15e0224852. 10.1371/journal.pone.0224852. 32214346.
45. Wu X, Gao Y, Xu L, et al. Exosomes from high glucose-treated glomerular endothelial cells trigger the epithelial-mesenchymal transition and dysfunction of podocytes. Sci Rep 2017;7:9371. 10.1038/s41598-017-09907-6. 28839221.
46. Wang YY, Tang LQ, Wei W. Berberine attenuates podocytes injury caused by exosomes derived from high glucose-induced mesangial cells through TGFβ1-PI3K/AKT pathway. Eur J Pharmacol 2018;824:185–192. 10.1016/j.ejphar.2018.01.034. 29378192.
47. Ling L, Tan Z, Zhang C, et al. CircRNAs in exosomes from high glucose-treated glomerular endothelial cells activate mesangial cells. Am J Transl Res 2019;11:4667–4682. 31497190.
48. Su H, Qiao J, Hu J, et al. Podocyte-derived extracellular vesicles mediate renal proximal tubule cells dedifferentiation via microRNA-221 in diabetic nephropathy. Mol Cell Endocrinol 2020;518:111034. 10.1016/j.mce.2020.111034. 32926967.
49. Huang Y, Li R, Zhang L, et al. Extracellular vesicles from high glucose-treated podocytes induce apoptosis of proximal tubular epithelial cells. Front Physiol 2020;11:579296. 10.3389/fphys.2020.579296. 33224036.
50. Burger D, Thibodeau JF, Holterman CE, Burns KD, Touyz RM, Kennedy CR. Urinary podocyte microparticles identify prealbuminuric diabetic glomerular injury. J Am Soc Nephrol 2014;25:1401–1407. 10.1681/asn.2013070763. 24676640.
51. Munkonda MN, Akbari S, Landry C, et al. Podocyte-derived microparticles promote proximal tubule fibrotic signaling via p38 MAPK and CD36. J Extracell Vesicles 2018;7:1432206. 10.1080/20013078.2018.1432206. 29435202.
52. Jeon JS, Kim E, Bae YU, et al. microRNA in extracellular vesicles released by damaged podocytes promote apoptosis of renal tubular epithelial cells. Cells 2020;9:1409. 10.3390/cells9061409. 32517075.
53. Zhao S, Li W, Yu W, et al. Exosomal miR-21 from tubular cells contributes to renal fibrosis by activating fibroblasts via targeting PTEN in obstructed kidneys. Theranostics 2021;11:8660–8673. 10.7150/thno.62820. 34522205.
54. Liu X, Liu Z, Wang C, et al. Kidney tubular epithelial cells control interstitial fibroblast fate by releasing TNFAIP8-encapsulated exosomes. Cell Death Dis 2023;14:672. 10.1038/s41419-023-06209-w. 37828075.
55. Wu T, Ding L, Andoh V, Zhang J, Chen L. The mechanism of hyperglycemia-induced renal cell injury in diabetic nephropathy disease: an update. Life (Basel) 2023;13:539. 10.3390/life13020539. 36836895.
56. Tsai YC, Kuo MC, Hung WW, et al. Proximal tubule-derived exosomes contribute to mesangial cell injury in diabetic nephropathy via miR-92a-1-5p transfer. Cell Commun Signal 2023;21:10. 10.1186/s12964-022-00997-y. 36639674.
57. Wen J, Ma Z, Livingston MJ, et al. Decreased secretion and profibrotic activity of tubular exosomes in diabetic kidney disease. Am J Physiol Renal Physiol 2020;319:F664–F673. 10.1152/ajprenal.00292.2020. 32715764.
58. Lu Y, Zhang R, Gu X, Wang X, Xi P, Chen X. Exosomes from tubular epithelial cells undergoing epithelial-to-mesenchymal transition promote renal fibrosis by M1 macrophage activation. FASEB Bioadv 2023;5:101–113. 36876297.
59. Lv LL, Feng Y, Wen Y, et al. Exosomal CCL2 from tubular epithelial cells is critical for albumin-induced tubulointerstitial inflammation. J Am Soc Nephrol 2018;29:919–935. 10.1681/asn.2017050523. 29295871.
60. Lv LL, Feng Y, Wu M, et al. Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury. Cell Death Differ 2020;27:210–226. 10.1038/s41418-019-0349-y. 31097789.
61. Ding C, Zheng J, Wang B, et al. Exosomal MicroRNA-374b-5p from tubular epithelial cells promoted M1 macrophages activation and worsened renal ischemia/reperfusion injury. Front Cell Dev Biol 2020;8:587693. 10.3389/fcell.2020.587693. 33324643.
62. Li ZL, Lv LL, Tang TT, et al. HIF-1α inducing exosomal microRNA-23a expression mediates the cross-talk between tubular epithelial cells and macrophages in tubulointerstitial inflammation. Kidney Int 2019;95:388–404. 10.1016/j.kint.2018.09.013. 30551896.
63. Zhou X, Zhao S, Li W, et al. Tubular cell-derived exosomal miR-150-5p contributes to renal fibrosis following unilateral ischemia-reperfusion injury by activating fibroblast in vitro and in vivo. Int J Biol Sci 2021;17:4021–4033. 10.7150/ijbs.62478. 34671216.
64. Recio C, Lazaro I, Oguiza A, et al. Suppressor of cytokine signaling-1 peptidomimetic limits progression of diabetic nephropathy. J Am Soc Nephrol 2017;28:575–585. 10.1681/asn.2016020237. 27609616.
65. Dominguez JH, Liu Y, Gao H, Dominguez JM, Xie D, Kelly KJ. Renal tubular cell-derived extracellular vesicles accelerate the recovery of established renal ischemia reperfusion injury. J Am Soc Nephrol 2017;28:3533–3544. 10.1681/asn.2016121278. 28747315.
66. Xu W, Xu R, Li Z, Wang Y, Hu R. Hypoxia changes chemotaxis behaviour of mesenchymal stem cells via HIF-1α signalling. J Cell Mol Med 2019;23:1899–1907. 10.1111/jcmm.14091. 30628201.
67. Li L, Fu H, Liu Y. The fibrogenic niche in kidney fibrosis: components and mechanisms. Nat Rev Nephrol 2022;18:545–557. 10.1038/s41581-022-00590-z. 35788561.
68. Sato Y, Yanagita M. Resident fibroblasts in the kidney: a major driver of fibrosis and inflammation. Inflamm Regen 2017;37:17. 10.1186/s41232-017-0048-3. 29259716.
69. Leaf IA, Nakagawa S, Johnson BG, et al. Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury. J Clin Invest 2017;127:321–334. 10.1172/jci87532. 27869651.
70. LeBleu VS, Taduri G, O’Connell J, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2013;19:1047–1053. 10.1038/nm.3218. 23817022.
71. Zhou Y, Xiong M, Niu J, et al. Secreted fibroblast-derived miR-34a induces tubular cell apoptosis in fibrotic kidney. J Cell Sci 2014;127:4494–4506. 25107369.
72. Li H, Xu Y, Zhang Q, Xu H, Xu Y, Ling K. Microvesicles containing miR-34a induce apoptosis of proximal tubular epithelial cells and participate in renal interstitial fibrosis. Exp Ther Med 2019;17:2310–2316. 10.3892/etm.2019.7197. 30867715.
73. Medina RJ, Barber CL, Sabatier F, et al. Endothelial progenitors: a consensus statement on nomenclature. Stem Cells Transl Med 2017;6:1316–1320. 10.1002/sctm.16-0360. 28296182.
74. Cantaluppi V, Gatti S, Medica D, et al. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int 2012;82:412–427. 10.1038/ki.2012.105. 22495296.
75. Tang TT, Wang B, Wu M, et al. Extracellular vesicle-encapsulated IL-10 as novel nanotherapeutics against ischemic AKI. Sci Adv 2020;6eaaz0748. 10.1126/sciadv.aaz0748. 32851154.
76. Huang H, Liu H, Tang J, et al. M2 macrophage-derived exosomal miR-25-3p improves high glucose-induced podocytes injury through activation autophagy via inhibiting DUSP1 expression. IUBMB Life 2020;72:2651–2662. 10.1002/iub.2393. 33107695.
77. Zhuang Y, Zheng H, Yang Y, Ni H. GABA alleviates high glucose-induced podocyte injury through dynamically altering the expression of macrophage M1/M2-derived exosomal miR-21a-5p/miR-25-3p. Biochem Biophys Res Commun 2022;618:38–45. 10.1016/j.bbrc.2022.06.019. 35714569.
78. Wang Z, Sun W, Li R, Liu Y. miRNA-93-5p in exosomes derived from M2 macrophages improves lipopolysaccharide-induced podocyte apoptosis by targeting toll-like receptor 4. Bioengineered 2022;13:7683–7696. 10.1080/21655979.2021.2023794. 35291915.
79. Grange C, Papadimitriou E, Dimuccio V, et al. Urinary extracellular vesicles carrying klotho improve the recovery of renal function in an acute tubular injury model. Mol Ther 2020;28:490–502. 10.1016/j.ymthe.2019.11.013. 31818691.
80. Zheng Y, Wang H, Li X, Xie J, Fan J, Ren S. Extracellular vesicles in chronic kidney disease: diagnostic and therapeutic roles. Front Pharmacol 2024;15:1371874. 10.3389/fphar.2024.1371874. 38545551.
81. Lange T, Artelt N, Kindt F, et al. MiR-21 is up-regulated in urinary exosomes of chronic kidney disease patients and after glomerular injury. J Cell Mol Med 2019;23:4839–4843. 10.1111/jcmm.14317. 31066165.
82. Jia Y, Guan M, Zheng Z, et al. miRNAs in urine extracellular vesicles as predictors of early-stage diabetic nephropathy. J Diabetes Res 2016;2016:7932765. 10.1155/2016/7932765. 26942205.
83. Khurana R, Ranches G, Schafferer S, et al. Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease. RNA 2017;23:142–152. 10.1261/rna.058834.116. 27872161.
84. Sigdel TK, Ng YW, Lee S, et al. Perturbations in the urinary exosome in transplant rejection. Front Med (Lausanne) 2015;1:57. 10.3389/fmed.2014.00057. 25593928.
85. Alvarez S, Suazo C, Boltansky A, et al. Urinary exosomes as a source of kidney dysfunction biomarker in renal transplantation. Transplant Proc 2013;45:3719–3723. 10.1016/j.transproceed.2013.08.079. 24315007.
86. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997;90:3819–3843. 10.1182/blood.v90.10.3819. 9354649.
87. Mossberg M, Ståhl AL, Kahn R, et al. C1-inhibitor decreases the release of vasculitis-like chemotactic endothelial microvesicles. J Am Soc Nephrol 2017;28:2472–2481. 10.1681/asn.2016060637. 28289183.
88. Liu X, Miao J, Wang C, et al. Tubule-derived exosomes play a central role in fibroblast activation and kidney fibrosis. Kidney Int 2020;97:1181–1195. 10.1016/j.kint.2019.11.026. 32139089.
89. Tang TT, Wang B, Lv LL, Dong Z, Liu BC. Extracellular vesicles for renal therapeutics: State of the art and future perspective. J Control Release 2022;349:32–50. 10.1016/j.jconrel.2022.06.049. 35779658.
90. Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005;289:F31–F42. 10.1152/ajprenal.00007.2005. 15713913.
91. Bruno S, Grange C, Deregibus MC, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009;20:1053–1067. 10.1681/asn.2008070798. 19389847.
92. Ceccotti E, Saccu G, Herrera Sanchez MB, Bruno S. Naïve or engineered extracellular vesicles from different cell sources: therapeutic tools for kidney diseases. Pharmaceutics 2023;15:1715. 10.3390/pharmaceutics15061715. 37376163.
93. Welsh JA, Goberdhan DC, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles 2024;13e12404. 38326288.
94. Cheng K, Kalluri R. Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics. Extracellular Vesicle 2023;2:100029. 10.1016/j.vesic.2023.100029.

Article information Continued

Figure 1.

The roles of EVs from TECs during the onset of renal diseases.

EVs from TECs can deliver biomolecules to other cells within the nephron. External signals, such as fibrotic stimulus (TGF-β1), high glucose, protein (BSA), or hypoxia, stimulate TECs, inducing EV production. Subsequently, EVs are taken up by other cells, contributing to inflammation through M1 polarization of macrophages and fibrosis via myofibroblastic activation of renal fibroblasts and mesangial cells.

BSA, bovine serum albumin; CCL2, chemokine (C-C motif) ligand 2; EV, extracellular vesicles; TEC, tubular epithelial cells; TGF-β1, transforming growth factor-beta 1; TNFAIP8, tumor necrosis factor-alpha-induced protein 8.

Table 1.

Molecular contents and function of EVs derived from glomerular cells and their pathological roles in kidney cells

EV source In vitro/in vivo EV contents Responding cell or animal Type of injury Key findings Reference
HG- or PAN-treated glomerular endothelial cell In vitro miRNA-200c-3p Podocyte DKD, inflammation Podocyte dysfunction [43]
Increased OCR, ATP production, and ROS production
Decreased VEGF secretion
HG-treated mouse kidney glomerular endothelial cell In vitro TGF-β1 mRNA Mouse podocyte cell line DN EMT and dysfunction of podocyte [44]
Decreased expression of nephrin, ZO-1, and WT-1
Increased expression of α-SMA, FSP-1, desmin, active β-catenin, and Snail
HG-treated glomerular mesangial cell In vitro TGF-β1 Primary podocyte DN Podocyte injury [45]
Decreased cell adhesion and nephrin, podocin, and WT-1 expression
Increased apoptosis and TGF-βR, PI3K, p-AKT, p-p65, and TGFβ-R1 expression
HG-treated glomerular endothelial cell In vitro Decreased circRNF169-2 and circSTRN3-2 levels Glomerular mesangial cell DN Proliferation inhibition and EMT promotion [46]
Increased α-SMA expression and cell migration
HG-treated human podocyte In vitro miR-221 HK-2 (human tubular epithelial cell) DN Cell injury [47]
Decreased ZO-1 and E-CAD expression
Increased vimentin expression
HG-treated mouse podocyte In vitro Decreased miR-1981-3p, miR-3747, miR-7224-3p, and miR-6538 levels Mouse proximal tubular epithelial cells from HG-treated or normoxic mice DKD Increased apoptosis [48]
Increased miR-let-7f-2-3p levels Increased number of annexin V- and TUNEL-positive cells
HG-treated podocytes In vivo Not described Not described DN Increased the number of microparticles in STZ, Akita, OVE26 mouse [49]
Human podocyte cell line In vitro Non-described Human proximal tubular epithelial cell DN Profibrotic response [50]
Upregulated p-Smad3, fibronectin, collagen IV, and p-p38 expression
PAN-treated human podocyte In vitro miR-149 HK-2 (human tubular epithelial cell) Glomerulosclerosis Increased apoptosis [51]
miR-424 Increased expression of cleaved PARP, p-ERK, p-p38, fibronectin, and collagen IV

α-SMA, alpha-smooth muscle actin; AKT, protein kinase B; ATP, adenosine triphosphate; circ, circular RNA; COL, collagen type IV; DKD, diabetic kidney disease; DN, diabetic nephropathy; E-CAD, epithelial cadherin; EMT, epithelial-to-mesenchymal transition; ERK, extracellular signal-regulated kinase; EV, extracellular vesicle; FSP-1, ferroptosis suppressor protein 1; HG, high glucose; miRNA, microRNA; OCR, oxygen consumption rate; PAN, puromycin aminonucleosides; PARP, poly(ADP-ribose) polymerase; PI3K, phosphoinositide 3-kinase; p-, phosphorylated; ROS, reactive oxygen species; STZ, streptozotocin; TGF, transforming growth factor; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; VEGF, vascular endothelial growth factor; WT-1, Wilms’ tumor-1; ZO-1, zonula occludens-1.

Table 2.

Molecular contents of EVs derived from tubular epithelial cells and their pathological roles in kidney

EV source EV contents Type of injury In vitro/in vivo Responding cell or animal Key findings Reference
TGF-β1–treated NRK-52E miR-21 CKD In vitro NRK-49F Increased fibroblast activation through the PTEN/AKT pathway [52]
Increased α-SMA, PCNA, fibronectin, and collagen I expression
Activation of p-AKT/AKT signaling
Decreased PTEN expression
In vivo UUO mice Progression of renal fibrosis through the PTEN/AKT pathway
Increased FSP-1, PCNA, collagen I, α-SMA, and fibronectin expression
Activation of p-AKT/AKT signaling
Decreased PTEN expression
TGF-β1–treated HK-2 TNFAIP8 CKD In vitro Cisplatin-induced NRK-49F Decreased apoptosis [53]
Increased myofibroblastic activation
Decreased number of TUNEL-positive cells
Decreased p53, cleaved caspase 3, FADD, PARP-1, BAX, and FasL expression
Increased fibrotic area
Increased fibronectin, α-SMA, Cyclin D1, and c-Myc expression
In vivo UUO mice Decreased fibroblast apoptosis
Increased myofibroblastic activation
Decreased expression of p53, cleaved caspase 3, FasL, FADD, and PARP-1
Increased expression of FSP-1, fibronectin, α-SMA, and vimentin
HG-treated HK-2 miR-92a-1-5p DN In vitro Mouse mesangial cell Increased myofibroblast transdifferentiation [55]
Increased N-cadherin and vimentin expression
Decreased E-cadherin expression
In vivo Diabetic mice Progression to DN
Increased urinary levels of ACR, KIM-1/Cr, and NGAL/Cr
HG-mouse kidney proximal tubular cell line (BUMPT) Two protein-protein interaction networks DKD In vitro NRK-49F Increased myofibroblast activation [56]
Increased expression of fibronectin, α-SMA, and collagen I
TGF-β–treated TEC (TCMK-1; mouse renal tubular cell line) Non-described CKD In vitro RAW264.7 M1 polarization [57]
Increased iNOS, α-SMA, TNF-α, IL-1β, and IL-6 expression
Decrease of IL-10 expression
In vivo UUO mice EMT-like process and M1 macrophage activation
Increase of SCr and BUN
Increased expression of TNF-α, iNOS, IL-1β, IL-6, fibrotic area, α-SMA, CD86 positive cell, Vimentin, Snail-1, MCP-1, and FSP-1
Decreased IL-10 and E-cadherin expression
BSA-induced mouse TEC CCL2 (cytokine mRNA) AKI In vitro Raw264.7 (macrophage) Increased inflammatory response and macrophage migration [58]
Increased expression of TNF-α, CCL2, IL-1β, and IL-6
In vivo Mice Increased renal inflammation and tubular injury
Increased PAS-stained area
Increased expression of CD68 and NGAL
BSA-treated mTEC miR-19b-3p Tubulointerstitial inflammation In vitro Raw264.7 Increased M1 polarization [59]
Increased expression of MCP-1, IL-1α, TNF-α, IL-6, and iNOS
In vivo Mice Inflammation
Increased PAS-stained area
Increased expression of F4/80, IL-6, and MCP-1
Hypoxia-conditioned 293T cells (1% O2, 5% CO2) miR-374b-5p RIRI In vitro Raw264.7 Increased M1 polarization [60]
Increased expression of CD86, iNOS, and TNF-α
In vivo RIR Increased inflammation and M1 polarization of macrophages
Increased SCr and BUN expression
Increased expression of MCP-1, TNF-α, and IL-1α
Hypoxia-conditioned mouse TECs miR-23a Tubulointerstitial inflammation In vitro Raw 264.7 Increase of tubulointerstitial inflammation [61]
Increased expression of MCP-1, TNF-α, IL-1β, and p-p65
In vivo Mice Stimulation of injury by macrophage accumulation
Increased expression of MCP-1, TNF-α, IL-1β, p-p65, and p65
Decreased expression of A20
Hypoxia-conditioned NRK-52E miR-150-5p UIRI In vitro NRK-49F Fibroblast activation [62]
Increased expression of α-SMA and fibronectin
In vivo UIRI Increased fibrotic area
Increased expression of α-SMA, Fibronectin, and SOCS1
Increased area of Sirius red staining
Hypoxia (4 hr)-conditioned rat primary tubular cells Non-described AKI In vivo AKI by IRI in rats Accelerated recovery of IRI [64]
Decreased 4-HNE formation, neutrophil infiltration, and fibrosis

α-SMA, alpha-smooth muscle actin; ACR, acrosin; AKI, acute kindey injury; AKT, protein kinase B; BAX, Bcl-2-associated protein x; BSA, bovine serum albumin; BUMPT, Boston University mouse proximal tubular cell-clone 306; BUN, blood urea nitrogen; CCL2, chemokine (C-C motif) ligand 2; CD, cluster of differentiation; CKD, chronic kidney disease; c-Myc, cellular Myc proto-oncogene protein; Cr, creatinine; DKD, diabetic kidney disease; DN, diabetic nephropathy; E-CAD, epithelial cadherin; EMT, epithelial-to-mesenchymal transition; EV, extracellular vesicle; FADD, Fas-associated via death domain; FasL, Fas ligand; FSP-1, ferroptosis suppressor protein 1; HG, high glucose; IL, interleukin; iNOS, inducible nitric oxide synthase; IRI, ischemia-reperfusion injury; KIM, kidney injury molecule; MCP-1, monocyte chemoattractant protein-1; mTEC, mouse tubular epithelial cell; NGAL, neutrophil gelatinase-associated lipocalin; p-, phosphorylated; PARP-1, poly(ADP-ribose) polymerase-1; PAS, periodic acid–Schiff; PCNA, proliferating cell nuclear antigen; PTEN, phosphatase and tensin homolog; RIR, retinal ischemia-reperfusion; RIRI, renal ischemia-reperfusion injury; SCr, serum creatinine; SOCS1, suppressor of cytokine signaling 1; TCMK-1, transformed C3H mouse kidney-1; TEC, tubular epithelial cell; TGF, transforming growth factor; TNFAIP8, tumor necrosis factor alpha-induced protein 8; TNF-α, tumor necrosis factor alpha; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; UIRI, unilateral ischemia-reperfusion injury; UUO, unilateral ureteral obstruction; 4-HNE, 4-hydroxynonenal.

Table 3.

Effects of EVs from other cells on their pathological role in kidney cells

EV source In vitro/in vivo EV contents Responding cell or animal Key findings References
TGF-β1-treated renal fibroblasts In vitro and in vivo miR-34a Renal tubular cells Increased number of MVs by TGF-β1 treatment [71,72]
Increased apoptosis of TECs in vitro and in vivo
Primary endothelial progenitor cells In vivo Non-described Acute renal IRI in Wistar rats Protection of renal function [74]
Decreased levels of serum creatinine, BUN, and apoptosis
Decreased tubulointerstitial fibrosis and glomerulosclerosis
In vitro miR-126 Hypoxic peritubular endothelial cells Decreased apoptosis
miR-296 Enhanced angiogenesis
Hypoxic tubular epithelial cells Decreased apoptosis
Decreased level of caspase activation
IL-10-transfected Raw264.7 In vivo IL-10 Ischemic AKI mice Enhanced mitophagy and mitochondrial fitness in TECs [75]
M2 polarization of interstitial macrophages
Decreased level of serum creatinine and fibrotic area
Decreased collagen I, α-SMA, cleaved caspase 3, CD68, and CD3 expression
Increased CD206-expressing cells
IL-4-induced Raw264.7 In vitro miR-25-3p HG-stimulated mouse podocyte cell line Increased autophagy and protection against injury [76]
Decreased apoptotic cell death
Decreased vimentin, α-SMA, LC3-II, Beclin-1, and p62 expression
Increased P-CAD, ZO-1, and E-CAD expression
High glucose Raw264.7 In vitro miR-25-3p Mouse podocyte Increased apoptosis [77]
Decreased Tnpo1 expression
miR-21a-5p Mouse podocyte Increased apoptosis
Decreased AXTN3
IL-4-induced Raw 264.7 In vitro miR-93-5p LPS-induced mouse podocyte Suppression of apoptosis [78]
Decreased expression of cleaved caspase 3 and BAX
Increased Bcl-2 expression
Healthy human urine In vivo Klotho AKI mouse Improvement in renal function and tubular proliferation [79]
Decreased NGAL, PAI, SOX9, caspase 3, TNF-α, IL-1β, IL-6, NF-κB, CTGF, and α-SMA expression
Decreased SCr and BUN expression

AKI, acute kidney injury; α-SMA, alpha-smooth muscle actin; AXTN3, ataxin 3; BAX, Bcl-2-associated protein x; Bcl-2, B-cell lymphoma/leukemia-2; BUN, blood urea nitrogen; CTGF, connective tissue growth factor; E-CAD, epithelial cadherin; EV, extracellular vesicle; HG, high glucose; IL, interleukin; IRI, ischemia-reperfusion injury; LPS, lipopolysaccharide; MV, microvesicle; NF-κB, nuclear factor kappa B; NGAL, neutrophil gelatinase-associated lipocalin; PAI, plasminogen activator inhibitor; P-CAD, placental cadherin; SCr, serum creatinine; SOX9, SRY-Box transcription factor 9; TEC, tubular epithelial cell; TGF, transforming growth factor; TNF, tumor necrosis factor; Tnpo1, transportin-1; ZO-1, zonula occludens-1.